Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.50
+0.04 (0.70%)
At close: Aug 1, 2025, 4:00 PM
6.48
-0.01 (-0.23%)
After-hours: Aug 1, 2025, 4:10 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $14.67, which forecasts a 125.87% increase in the stock price over the next year. The lowest target is $10 and the highest is $19.
Price Target: $14.67 (+125.87%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 28, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +53.96% | May 28, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 1, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $16 → $15 | Strong Buy | Maintains | $16 → $15 | +130.95% | Nov 19, 2024 |
| Piper Sandler | Piper Sandler | Buy Initiates $19 | Buy | Initiates | $19 | +192.53% | Oct 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 9, 2024 |
Financial Forecast
Revenue This Year
63.78M
from 155.84M
Decreased by -59.07%
Revenue Next Year
65.00M
from 63.78M
Increased by 1.92%
EPS This Year
-1.28
from 0.14
EPS Next Year
-1.43
from -1.28
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 98.2M | 108.0M | 123.7M | ||
| Avg | 63.8M | 65.0M | 83.7M | ||
| Low | 40.3M | 28.5M | 4.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -37.0% | 69.3% | 90.3% | ||
| Avg | -59.1% | 1.9% | 28.8% | ||
| Low | -74.2% | -55.2% | -93.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.00 | -1.05 | -1.09 | ||
| Avg | -1.28 | -1.43 | -1.40 | ||
| Low | -1.42 | -1.95 | -1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.